Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Proposes Biggest Mammography Rule Change In 20 Years

Executive Summary

US FDA wants to make significant changes to how mammographers interact with patients in terms of the information they share about the procedure and standards they will have to follow. The issue specifically addresses scenarios where patients with denser breast tissue may not be fully informed about the accuracy of their mammography tests. If the agency's proposal moves forward, it will be the biggest regulatory change for the mammography industry in more than two decades.

You may also be interested in...

American Society Of Breast Surgeons Releases First Mammography Screening Guidelines

In a move which conflicts with guidelines from other organizations, the American Society of Breast Surgeons released its first mammography screening guidelines, recommending among others, annual screenings for women starting at age 40.

FDA’s 2020 Device Budget Would Focus On Safety, Cybersecurity, Bringing Medtech 'Home'

US FDA intends to use device-center dollars in its fiscal year 2020 budget on medical product safety, bolstering cybersecurity, device oversight modernization, and an initiative called “Bring Medtech Manufacturing Home,” among other priorities.

Market Intel: Breast Imaging Market Driven By AI, Technological Innovation

The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts